Drug intelligence / Profile preview

Volvics

Development stage: Unknown
Lead developer: Yakult Honsha
Modality: Small Molecules
Administration: Intravenous

Overview

Volvics is a trace element injection developed by Yakult Honsha for use in high-calorie parenteral nutrition (HPN). It is designed to provide essential trace elements—typically including iron, manganese, zinc, copper, and iodine—to patients receiving long-term intravenous nutrition to prevent deficiencies. The product is administered as an additive to high-calorie infusions. While it has been approved and marketed in Japan, recent pipeline information indicates it is being discontinued.

Brand names: VolvicsVolvics Injectionボルビックス注
Other names: trace element injection

Beyond the preview

Go deeper on Volvics.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Volvics.

Explore the full profile